Neostem’s Suzhou Eyre receives Chinese Regulatory Approval For 6th Production Line
NeoStem announced Monday that its subsidiary, Suzhou Eyre Pharmaceuticals, has received approval for its sixth production line.
Featured Articles
e-Zassi To Present Solution To Fractured Medical Device Ecosystem
e-Zassi is the medical device industry’s first subscription-based, decision support software and technology marketplace.
ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
A panel at OneMedForum NY 2011 will explore strategic planning considerations in the process of getting approval and reimbursement.
Rib-X Pharmaceuticals’ Nobel Prize Winning Platform Combats Serious Infections
The antibiotic market is expected to reach $45 billion by 2012 driven by the deficiencies of currently available antibiotics.
Small Bone Innovations Addresses Unmet Needs in Joint Replacement
Orthopedic companies have focused on developing devices for large bone trauma, leaving the small bone and joint field lacking.
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
Hepregen Awarded $500,000 Massachusetts Life Sciences Center Grant
Hepregen, a leading provider of bioengineered solutions that increase success in drug development, was awarded a $500,000 grant as part of the Small Business Matching Grants program
Phytoceuticals Heals Wounds Through An Easy To Use Spray
This is a new solution that is poised to become the standard of care in wound management because of effective speed, ease of use and cost savings.
GlySure’s Technology May Break Barrier For Tight Control And Automated Glucose Monitoring
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.